Fewer than half of patients with multiple sclerosis respond to interferon-b, one of the most widely prescribed therapies. The discovery that different subtypes of T cells may be involved in disease development in each affected individual suggests that it may be possible to predict therapeutic success by determining a patient's cytokine profile (pages 406–412).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The conundrum of iron in multiple sclerosis – time for an individualised approach
Metabolic Brain Disease Open Access 17 March 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rudick, R.A. & Polman, C.H. Lancet Neurol. 8, 545–559 (2009).
Axtell, R.C. et al. Nat. Med. 16, 406–412 (2010).
Steinman, L. J. Exp. Med. 205, 1517–1522 (2008).
Mestas, J. & Hughes, C.C.W. J. Immunol. 172, 2731–2738 (2004).
Tzartos, J.S. et al. Am. J. Pathol. 172, 146–155 (2008).
Durelli, L. et al. Ann. Neurol. 65, 499–509 (2009).
Ramgolam, V.S., Sha, Y.G., Jin, J.P., Zhang, X. & Markovic-Plese, S. J. Immunol. 183, 5418–5427 (2009).
Byrnes, A.A., McArthur, J.C. & Karp, C.L. Ann. Neurol. 51, 165–174 (2002).
Wandinger, K.P. et al. Lancet 361, 2036–2043 (2003).
Comabella, M. et al. Brain 132, 3353–3365 (2009).
Baranzini, S.E. et al. PLoS Biol. 3, e2 (2005).
Bielekova, B. & Martin, R. Brain 127, 1463–1478 (2004).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Part of H.W.’s research have been supported by Novartis and Morphosys. He has received speaker’s honoraria from multiple companies. R.H. received consultancy fees or grant support from pharmaceutical companies marketing or developing treatments for multiple sclerosis, including Bayer, Teva, Sanofi, Biogen-Idec, Merck-Serono and Novartis.
Rights and permissions
About this article
Cite this article
Wekerle, H., Hohlfeld, R. Molecular oracles for multiple sclerosis therapy. Nat Med 16, 376–377 (2010). https://doi.org/10.1038/nm0410-376
Issue Date:
DOI: https://doi.org/10.1038/nm0410-376
This article is cited by
-
The conundrum of iron in multiple sclerosis – time for an individualised approach
Metabolic Brain Disease (2012)